English, Article edition: Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients Adrian D. Griffin; Andrew S. Perry; Douglas M. Fleming

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119540
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients
Author
  • Adrian D. Griffin
  • Andrew S. Perry
  • Douglas M. Fleming
Physical Description
  • article
Notes
  • Objective: To evaluate the cost effectiveness of zanamivir 10mg twice daily for 5 days in the treatment of influenza in high-risk patients. Design: Bootstrap cost-effectiveness analysis incorporating within-trial analysis of pooled patient-level cost and effect data. Setting: UK unit costs and utilities applied to high-risk patients drawn from 6 multinational clinical trials. Patients: A total of 154 zanamivir and 167 placebo high-risk patients were included in the analysis. Main outcome measures: Cost per day of normal activities; cost per symptom-free day; cost per complication averted; cost per quality-adjusted life-year (QALY). Results: The mean benefit was estimated to be 2.5 days [95% confidence interval (CI): 0.68 to 4.27] of normal activities gained; 2.0 (95% CI: 0.56 to 3.51) symptom-free days; and a 9% reduction in complications (95% CI: 0 to 18%). Excluding the effect of rare hospitalisation costs, the cost (1999 values) of gaining a day of normal activities was Lstg 9.50 (95% CI: Lstg 5 to Lstg 39); cost per symptom-free day was Lstg 11.56 (95% CI: Lstg 6 to Lstg 43); cost per complication averted was Lstg 262 (95% CI: Lstg 90 to Lstg 1574). Influenza was estimated to reduce utility by 0.883 per day, demonstrating the debilitating effect of the disease. Extrapolating a day of normal activities to a standard utility measure resulted in a cost per QALY of Lstg 3900 excluding inpatient costs (Lstg 7490 including inpatient costs). Cost-effectiveness acceptability curves demonstrated 90% certainty that zanamivir would be cost effective at Lstg 8000 per QALY. Conclusions: Significant health benefits can be obtained with zanamivir treatment in high-risk patients. The cost per QALY for zanamivir in these patients compares well with that of other commonly used pharmacological interventions.
  • Antivirals, Cost utility, Influenza A virus infections, Influenza B virus infections, Pharmacoeconomics, Zanamivir
  • RePEc:wkh:phecon:v:19:y:2001:i:3:p:293-301
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment